Exth-13. Reduction of Tumor Burden and Hearing Loss With a Multiple Receptor Tyrosine Kinase Inhibitor Brigatinib in a Genetically Engineered Mouse Model of Neurofibromatosis Type 2

Neuro-Oncology - United Kingdom
doi 10.1093/neuonc/noy148.362
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Oxford University Press (OUP)

Related search

Chemopreventative Celecoxib Fails to Prevent Schwannoma Formation or Sensorineural Hearing Loss in Genetically Engineered Murine Model of Neurofibromatosis Type 2

Oncotarget
Oncology
2017English

Adrenal Tumor Volume in a Genetically Engineered Mouse Model of Neuroblastoma Determined by Magnetic Resonance Imaging

Experimental and Therapeutic Medicine
MedicineCancer ResearchImmunologyMicrobiology
2012English

PD-0332991, a CDK4/6 Inhibitor, Significantly Prolongs Survival in a Genetically Engineered Mouse Model of Brainstem Glioma

PLoS ONE
Multidisciplinary
2013English

The Bruton’s Tyrosine Kinase Inhibitor Acalabrutinib Protects From Anaphylaxis in a Humanized Mouse Model

Journal of Allergy and Clinical Immunology
AllergyImmunology
2019English

Multiple Roles for the Receptor Tyrosine Kinase Axl in Tumor Formation

Cancer Research
Cancer ResearchOncology
2005English

Bioluminescent Approaches for Measuring Tumor Growth in a Mouse Model of Neurofibromatosis

Toxicologic Pathology
Forensic MedicineToxicologyPathologyCell BiologyMolecular Biology
2010English

Tyrosine Kinase Inhibitor NVP-BGJ398 Functionally Improves FGFR3-related Dwarfism in Mouse Model

Journal of Clinical Investigation
Medicine
2016English

Effector T Cell Subclasses Associate With Tumor Burden in Neurofibromatosis Type 1 Patients

Cancer Immunology, Immunotherapy
Cancer ResearchMedicineOncologyAllergyImmunology
2016English

Hair Depigmentation During Chemotherapy With a Class III/V Receptor Tyrosine Kinase Inhibitor

Archives of Dermatology
2006English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy